Dr. Jean-François Boileau

Academic title(s): 

Assistant Professor, Department of Surgery, McGill University

Associate Member, Gerald Bronfman Department of Oncology, McGill University

Dr. Jean-François Boileau
Contact Information
Phone: 
514-340-8222, ext. 24210
Email address: 
jean-francois.boileau [at] mcgill.ca
Biography: 

Dr. Boileau is a surgical oncologist and clinician scientist at the Montreal Jewish General Hospital. He has worked as staff surgeon at the Centre hospitalier universitaire de Montreal (CHUM) and at the Odette Cancer Centre of Sunnybrook Hospital in Toronto before transferring to his current position as assistant professor. His research interests are breast cancer and clinical trials.

Location: 
Jewish General Hospital (JGH)
Division: 
General surgery and oncology
Office: 
E776
Selected publications: 


1: Johnston S, Puhalla S, Wheatley D, Ring A, Barry P, Holcombe C, Boileau JF,
Provencher L, Robidoux A, Rimawi M, McIntosh SA, Shalaby I, Stein RC, Thirlwell
M, Dolling D, Morden J, Snowdon C, Perry S, Cornman C, Batten LM, Jeffs LK,
Dodson A, Martins V, Modi A, Osborne CK, Pogue-Geile KL, Cheang MCU, Wolmark N,
Julian TB, Fisher K, MacKenzie M, Wilcox M, Huang Bartlett C, Koehler M, Dowsett
M, Bliss JM, Jacobs SA. Randomized Phase II Study Evaluating Palbociclib in
Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early
Breast Cancer: PALLET Trial. J Clin Oncol. 2019 Jan 20;37(3):178-189. doi:
10.1200/JCO.18.01624. Epub 2018 Dec 6. PubMed PMID: 30523750.


2: Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang CS, Thompson AM, Harbeck N,
Valero V, Stroyakovskiy D, Wildiers H, Campone M, Boileau JF, Beckmann MW,
Afenjar K, Fresco R, Helms HJ, Xu J, Lin YG, Sparano J, Slamon D. Neoadjuvant
trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus
pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised,
open-label, multicentre, phase 3 trial. Lancet Oncol. 2018 Jan;19(1):115-126.
doi: 10.1016/S1470-2045(17)30716-7. Epub 2017 Nov 23. PubMed PMID: 29175149.


3: Wong SM, King T, Boileau JF, Barry WT, Golshan M. Population-Based Analysis of
Breast Cancer Incidence and Survival Outcomes in Women Diagnosed with Lobular
Carcinoma In Situ. Ann Surg Oncol. 2017 Sep;24(9):2509-2517. doi:
10.1245/s10434-017-5867-6. Epub 2017 Apr 28. PubMed PMID: 28455673.


4: Shakir SI, Pelmus M, Florea A, Boileau JF, Guiot MC, Di Maio S, Muanza TM.
Synchronous metastatic skull base chordoma to the breast: case report and
literature review. Curr Oncol. 2016 Apr;23(2):e154-7. doi: 10.3747/co.23.2896.
Epub 2016 Apr 13. PubMed PMID: 27122985; PubMed Central PMCID: PMC4835016.


5: Broglio KR, Quintana M, Foster M, Olinger M, McGlothlin A, Berry SM, Boileau
JF, Brezden-Masley C, Chia S, Dent S, Gelmon K, Paterson A, Rayson D, Berry DA.
Association of Pathologic Complete Response to Neoadjuvant Therapy in
HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis. JAMA Oncol.
2016 Jun 1;2(6):751-60. doi: 10.1001/jamaoncol.2015.6113. PubMed PMID: 26914222.


6: Torres S, Simmons C, Boileau JF, McLeod D, Martins I, Trudeau M. Patterns in
target-directed breast cancer research. Springerplus. 2016 Feb 1;5:109. doi:
10.1186/s40064-016-1736-1. eCollection 2016. PubMed PMID: 26877907; PubMed
Central PMCID: PMC4735094.


7: Simmons CE, Hogeveen S, Leonard R, Rajmohan Y, Han D, Wong A, Lee J,
Brackstone M, Boileau JF, Dinniwell R, Gandhi S. A Canadian national expert
consensus on neoadjuvant therapy for breast cancer: linking practice to evidence
and beyond. Curr Oncol. 2015 Mar;22(Suppl 1):S43-53. doi: 10.3747/co.22.2328.
PubMed PMID: 25848338; PubMed Central PMCID: PMC4381790.

View more

Areas of interest: 

All

The biology of cancer

Etiology (causes)

Prevention

Screening, diagnosis and prognosis

Treatment

Onco-psychology

The development of scientific models

Clinical Interests: 

Breast Cancer

Back to top